Distribution of total net revenues

SEK million

2018

Oct-Dec

2017

Oct-Dec

2018

Jan-Dec

2017

Jan-Dec

Zubsolv® US

166.7

126.5

621.5

485.8

Zubsolv – ex US

5.2

5.6

36.2

5.6

Zubsolv – total

171.9

132.1

657.8

491.4

Abstral® royalties

52.4

55.4

118.8

113.2

Edluar® royalties

2.9

3.6

6.6

17.3

OX-CLI

21.8

Total

227.1

191.0

783.1

643.7

 

Key figures

SEK million, unless otherwise stated

2018

Oct-Dec

2017

Oct-Dec

2018

Jan-Dec

2017

Jan-Dec

Δ

2017-2018

Net revenues

227.1

191.0

783.1

643.7

22%

whereof Zubsolv® US net revenue

166.7

126.5

621.5

485.8

28%

Cost of goods sold

-43.4

-50.3

-171.8

-164.4

4%

Operating expenses

-146.1

-110.6

-515.6

-421.9

22%

EBIT

37.6

30.1

95.8

57.4

67%

EBIT margin, %

16.6

15.8

12.2

8.9

3.3 ppt

US EBIT

62.0

19.8

198.3

73.7

169%

US EBIT margin, %

37.2

15.7

31.9

15.2

16.7 ppt

EBITDA

42.8

35.3

116.6

78.2

49%

Earnings per share, before dilution, SEK

1.49

0.77

3.99

0.67

496%

Earnings per share, after dilution, SEK

1.47

0.77

3.93

0.67

487%

Cash flow from operating activities

71.7

-23.0

242.0

146.6

65%

Cash and cash equivalents

589.8

327.9

589.8

327.9

80%

Cash flow

SEK million

2018

Oct-Dec

2017

Oct-Dec

2018

Jan-Dec

2017

Jan-Dec

Cash flow from operating activities

71.7

-23.0

242.0

146.6

Cash flow from investing activities

-3.9

-0.8

-6.2

-1.6

Cash from financing activities

0,0

-26.4

0.0

-85.4

Cash flow for the period

67.8

-50.2

235.8

59.6

Cash and cash equivalents at the end of the period

589.8

327.9

589.8

327.9